Patients with pemphigus vulgaris under pathology and on the background of prolonged use of high doses of glucocorticosteroid therapy – the possibility of influencing the glutathione system
Keywordspemphigus vulgaris, glucocorticosteroids, glutathione reductase, glutathione peroxidase, thiols
Introduction. Pemphigus vulgaris (PV) is a life-threatening disease of the skin and mucous membranes that is associated with IgG antibodies that target several types of keratinocyte antigens and cause epidermal lysis (acantholysis) via intracellular signaling that activates apoptotic enzymes (apoptolysis).
The aim of the study was to increase the effectiveness of treatment of patients with PV with the substantiation and development of modern methods of corrective therapy based on the study of indicators of changes in the balance of the thiol-disulfide system in the body of patients under pathological conditions and with prolonged use of high doses of glucocorticosteroid hormones (GCS).
Materials and research methods. There were examined 30 patients with PV (4 men and 26 women), who were hospitalized in KU «Zaporizhzhya Regional Skin and Venereal Clinical Dispensary» ZOR, Zaporizhzhia. At the time of observation, most of the patients were aged 61-70 years. As a comparison group, 20 practically healthy people were examined, constituting a control group.
Our studies were four-phase: before treatment; 2-3 weeks of maximum doses of glucocorticosteroids (stage I); 1.5-2 months before discharge from the hospital, when the patient was gradually reduced dose of systemic glucocorticosteroids and the selection of the optimal daily dose (stage II); after 5-6 months, when doses of hormones were minimal (2-3 tablets) in the absence of clinical manifestations of vesicles (stage III).
Results. Our pathogenetic therapy by GCS significantly led to an increase in the level of reduced glutathione (GSH), so in particular after the third treatment stage it was at 1.52 ± 0.13 mkm / mg protein, exceeding the same rate of the first and second stages of GCS administration by 87.65 and 61.70%, respectively (p <0.05). The course of GCS therapy in patients with PV contributed to the fact that the level of reduced thiols increased significantly during each stage of therapy of the examined patients, in particular in the third stage of maintenance GCS therapy reduced thiols were determined at 15.64 ±1.23 mM / mg protein, exceeding this marker of the second stage by 36.95%, and the value of reduced thiols of the first stage by 83.78% (p <0.05). The value of reduced thiols of the group of patients with PV in the second stage was 11.42 ±1.08 mM / mg protein, and in the first stage – 8.51 ±0.92 mM / mg protein, the percentage difference between these therapeutic stages was determined in 34.19% (p <0.05).
Prescribing systemic GCS to patients with PV for three stages led to the restoration of the balance of the thiol-disulfide system in patients, which manifested itself in the form of a decrease in markers: oxidized glutathione and oxidized thiols; and also in the form of an increase in the level of markers of restorative processes – glutathione reductase, glutathione peroxidase, reduced glutathione, reduced thiols, exerting a systemic positive effect on the course of the pathological process, which was reflected both in the normalization of laboratory parameters in patients and clinically in the form of stable remission.
Conclusion. GCS therapy helps to normalize the activity of the antioxidant system of the human body under conditions of PV pathology, which prevents deprivation of the glutathione chain of the thiol-disulfide system during activation of oxidative and nitrosative stress processes and prevents the development of decompensation of the antioxidant system as a whole with the development of damage to key cells and target organs.
Walker A., Favreau T. Localized pemphigus foliaceus // Cutis. 2017;99(1):P. 23–26.
Pemphigus in the eastern region of Turkey. Yavuz IH, Yavuz GO, Bayram I, Bilgili SG. Postepy Dermatol Alergol. 2019 Aug;36(4):455-460. doi: 10.5114/ada.2019.87449.
Pemphigus Foliaceus-Repeated Treatment With Rituximab 7 Years After Initial Response: A Case Report. Kraft M, Worm M. Front Med (Lausanne). 2018 Nov 9;5:315. doi: 10.3389/fmed.2018.00315.
Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference. Lee J, Werth VP, Hall RP 3rd, Eming R, Fairley JA, Fajgenbaum DC, Harman KE, Jonkman MF, Korman NJ, Ludwig RJ, Murrell DF, Musette P, Naik HB, Sadik CD, Yamagami J, Yale ML, Payne AS. Front Med (Lausanne). 2018 Nov 8;5:306. doi: 10.3389/fmed.2018.00306.
Treatment of pemphigus vulgaris: part 1 - current therapies. Yanovsky RL, McLeod M, Ahmed AR. Expert Rev Clin Immunol. 2019 Oct 10:1-14. doi: 10.1080/1744666X.2020.1672535.
Treatment of pemphigus vulgaris: part 2 - emerging therapies. Yanovsky RL, McLeod M, Ahmed AR. Expert Rev Clin Immunol. 2019 Oct 10:1-11. doi: 10.1080/1744666X.2020.1672539.
Papular Purpuric Glove and Socks Syndrome with Evolution into Pemphigus Vulgaris. Phuan CZ, Tan LS, Tey HL. Ann Acad Med Singapore. 2018 Oct;47(10):429-430.
"Change over time in the treatment of pemphigus vulgaris between 2004 and 2016 in Iran": A multiple cross-sectional study. Salarvand F, Fatehi Z, Shahali M, Balighi K, Ghiasi M, Abedini R, Mahmoudi H, Tavakolpour S, Chams-Davatchi C, Daneshpazhooh M. Dermatol Ther. 2019 Mar;32(2):e12827. doi: 10.1111/dth.12827.
Long noncoding RNA polymorphisms influence susceptibility to endemic pemphigus foliaceus. Lobo-Alves SC, Augusto DG, Magalhães WCS, Tarazona-Santos E, Lima-Costa MF, Barreto ML, Horta BL, de Almeida RC, Petzl-Erler ML. Br J Dermatol. 2019 Aug;181(2):324-331. doi: 10.1111/bjd.17640.
Etanercept for pemphigus vulgaris. Savoia F, Tabanelli M, Sechi A, Baraldi C, Bardazzi F, Patrizi A. G Ital Dermatol Venereol. 2019 Jan 9. doi: 10.23736/S0392-0488.18.06204-1.
Improving Treatment Outcome of Pemphigus Vulgaris on Vietnamese Patients by Using Desmoglein Elisa Test. Van ATT, Nguyen TV, Huu SN, Thi LP, Minh PPT, Huu N, Cam VT, Huyen ML, Nguyet MV, Hau KT, Gandolfi M, Satolli F, Feliciani C, Tirant M, Vojvodic A, Lotti T. Open Access Maced J Med Sci. 2019 Jan 22;7(2):195-197. doi: 10.3889/oamjms.2019.003.
Emerging role of immune cell network in autoimmune skin disorders: An update on pemphigus, vitiligo and psoriasis. Das D, Akhtar S, Kurra S, Gupta S, Sharma A. Cytokine Growth Factor Rev. 2019 Feb;45:35-44. doi: 10.1016/j.cytogfr.2019.01.001.
Autoimmunity and immunological tolerance in autoimmune bullous diseases. Takahashi H, Iriki H, Mukai M, Kamata A, Nomura H, Yamagami J, Amagai M. Int Immunol. 2019 Jul 13;31(7):431-437. doi: 10.1093/intimm/dxz030.
Factors Affecting the Duration of Phase 1 of Dexamethasone-Immunosuppressant Pulse Therapy for Pemphigus Group of Disorders: A 10-Year Retrospective Study in a Tertiary Care Center. Mundakkat V, Sridharan R. Indian Dermatol Online J. 2018 Nov-Dec;9(6):405-408. doi: 10.4103/idoj.IDOJ_74_18.
Pemphigus Vulgaris. Silva SC, Nasser R, Payne AS, Stoopler ET. J Emerg Med. 2019 Jan;56(1):102-104. doi: 10.1016/j.jemermed.2018.10.028.
Sporadic pemphigus foliaceus and class II human leucocyte antigen allele associations in the white British and Indo-Asian populations in the UK. Saha M, Harman K, Mortimer NJ, Binda V, Black MM, Kondeatis E, Vaughan R, Groves RW. Clin Exp Dermatol. 2019 Apr;44(3):290-294. doi: 10.1111/ced.13774.
Long-Term Increase of Kcnn4 Potassium Channel Surface Expression on B Cells in Pemphigus Patients after Rituximab Treatment. Caillot F, Derambure C, Berkani N, Riou G, Maho-Vaillant M, Calbo S, Joly P, Musette P. J Invest Dermatol. 2018 Dec;138(12):2666-2668. doi: 10.1016/j.jid.2018.05.034. Epub 2018 Jul 2.
Assessment of serious infections in pemphigus and pemphigoid by a national registry. Maglie R, Hertl M. J Eur Acad Dermatol Venereol. 2018 Oct;32(10):1623-1624. doi: 10.1111/jdv.15237.
Rituximab therapy in pemphigus: A long-term follow-up. Loi C, Magnano M, Ravaioli GM, Sacchelli L, Patrizi A, Bardazzi F. Dermatol Ther. 2019 Jan;32(1):e12763. doi: 10.1111/dth.12763.
How to Cite
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Number of views and downloads: 225
Number of citations: 0